Results 31 to 40 of about 481,968 (300)

Liver transplantation for viral hepatitis in 2015 [PDF]

, 2016
Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease and for patients with liver cell cancer related to liver disease.
Bortoluzzi, Ilaria, Burra, Patrizia, Ferrarese, Alberto, Gambato, Martina, Germani, Giacomo, Nadal, Elena, Russo, FRANCESCO PAOLO, Senzolo, Marco, Zanetto, Alberto   +8 more
core   +1 more source

Incidence, prevalence, and clinical course of hepatitis C following liver transplantation [PDF]

, 1992
Hepatitis C virus (HCV) is the agent responsible for posttransfusion hepatitis. The incidence, timing, and clinical course of HCV positive hepatitis in liver transplant recipients are unknown.
A.Jake Demetris, Aach, Alter, Barcena, Barrera, Brillanti, Choo, Colombo, David H. Van Thiel, Esteban, Esteban, Feinman, Grandele, Gray, Gunjan Shah, Hernandez, Jessica H. Lewis, Judith S. Gavaler, Kaplan, Knodell, Kuo, Kühnl, Mattsson, McFarlane, McHutchison, Noel, Poel, Read, Read, Rumi, Saturo Todo, Simonetti, Stevens, Thomas E. Starzl, Trainer, Weiner   +35 more
core   +1 more source

Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment [PDF]

, 2010
Background Early detection of nonresponders to hepatitis C therapy limits unnecessary exposure to treatment and its side-effects. A recent algorithm combining baseline anti-NS4a antibodies and on-treatment quantitative PCR identified nonresponders to a ...
de Knegt, Robert J, Desombere, Isabelle, Haagmans, Bart, Hansen, Bettina, Janssen, Harry LA, Leroux-Roels, Geert, Orlent, Hans, Schalm, Solko W, Van Vlierberghe, Hans   +8 more
core   +1 more source

CHRONIC HEPATITIS C

The Professional Medical Journal, 2010
Objectives: To know efficacy of combination of standard interferon α2b and ribavirin in chronic hepatitis C. Design: Prospective and analytical. Setting: CMH Bahawalpur. Period: Nov 2008 to Dec 2009. Materials and methods: A total of 126 patients, 104 males and 22 females, fulfilling inclusion and exclusion criteria were started combination treatment ...
SHAUKAT ALI, SYED KHURRAM SHAHZAD, ATIQ UR REHMAN SLEHRIA   +2 more
openaire   +4 more sources

The Association between Helicobacter pylori Infection and Chronic Hepatitis C: A Meta-Analysis and Trial Sequential Analysis

Gastroenterology Research and Practice, 2016
Purpose. Helicobacter pylori is a common gastric disease-inducing pathogen. Although an increasing number of recent studies have shown that H. pylori is a risk factor for liver disease, the potential association between H.
Juan Wang, Wen-Ting Li, Yi-Xiang Zheng, Shu-Shan Zhao, Ning Li, Yan Huang, Rong-Rong Zhou, Ze-Bing Huang, Xue-Gong Fan   +8 more
doaj   +1 more source

Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment

Journal of the Formosan Medical Association, 2021
Background/Purpose: Effective antiviral-therapy can reduce the risk of liver cirrhosis related hepatocellular carcinoma in patients with chronic hepatitis B and hepatitis C. Yet, the difference of hepatocellular carcinoma development in chronic hepatitis
Ming-Tsung Lin, Kuo-Chin Chang, Yi-Hao Yen, Ming-Chao Tsai, Chien-Hung Chen, Jing-Houng Wang, Chang-Chun Hsiao, Yueh-Hsia Chiu, Tsung-Hui Hu   +8 more
doaj   +1 more source

Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland

Swiss Medical Weekly, 2018
BACKGROUND The introduction of direct acting antivirals (DAAs) for the therapy of chronic hepatitis C (CHC) has revolutionised treatment and marks a paradigm shift in the approach to this disease, rendering interferon-based therapies obsolete.
Jacqueline A. Bachofner, Piero V. Valli, Irina Bergamin, Arne Kröger, Patrizia Künzler, Adriana Baserga, Dominique L. Braun, Burkhardt Seifert, Anja Moncsek, Jan Fehr, David Semela, Lorenzo Magenta, Beat Müllhaupt, Benedetta Terziroli Beretta-Piccoli, Joachim C. Mertens, the Swiss Hepatitis C Cohort Study   +15 more
doaj   +1 more source

Level of physicians’ awareness of epidemiology, outcomes, prevention and treatment of chronic hepatitis B and C [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2018
Objective. To evaluate a level of physicians’ awareness of the specific issues of epidemiology, outcomes, prevention and treatment of chronic hepatitis B and C. Materials and Methods.
Baramzina S.V.
doaj   +1 more source

Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis [PDF]

, 2000
Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects.
Amann, B., Grunze, Heinz, Loeschke, K., Schlösser, S., Schmidt, F., Schäfer, Martin   +5 more
core   +1 more source

Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism [PDF]

, 2003
Background. Tumor necrosis factor-alpha (TNF-alpha) is involved in the pathogenesis of chronic active hepatitis C. Polymorphisms in the promoter region of the TNF-alpha gene can alter the TNF-alpha expression and modify the host immune response.
Folwaczny, Christian, Glas, J., Konig, A., Martin, K., Schaefer, M., Schiemann, Uwe, Schmidt, F., Simperl, C., Torok, P.   +8 more
core   +1 more source